Cargando…

OR11-4 Teprotumumab Markedly Improves Disease-related Quality of Life: Lessons From Two Randomized, Placebo-controlled Trials

BACKGROUND: Thyroid eye disease (TED) can result in eye-bulging (proptosis) and double-vision (diplopia) and inflammation, which frequently impacts quality of life (QoL). Teprotumumab, an insulin like growth factor-1 receptor inhibitory antibody, improves TED outcomes and QoL(1) as measured by the G...

Descripción completa

Detalles Bibliográficos
Autores principales:	Douglas, Raymond S, Holt, Robert, Qashqai, Anahita, Sile, Saba, Smith, Terry J, Vesel, Claudia, Kahaly, George J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Thyroid
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627596/ http://dx.doi.org/10.1210/jendso/bvac150.1654

Ejemplares similares

OR18-01 Effect of Teprotumumab on Proptosis Reduction Across Various Demographic Sub-Groups
por: Kahaly, George J, et al.
Publicado: (2020)

SAT-554 Teprotumumab in Graves' Orbitopathy: Extended Outcome Analyses
por: Kahaly, George, et al.
Publicado: (2019)

PSAT261 Use of Steroids Pre- and Post-Teprotumumab in Thyroid Eye Disease Patients
por: Holt, Robert J, et al.
Publicado: (2022)

SAT461 Hearing-related Issues Associated With Graves’ Disease, Thyroid Eye Disease And Treatment With Teprotumumab
por: Smith, Terry J, et al.
Publicado: (2023)

PSAT265 Blood Glucose in Thyroid Eye Disease (TED) in Patients treated with Teprotumumab: Clinical Trials Data
por: Smith, Terry J, et al.
Publicado: (2022)

SAT459 Teprotumumab Pooled Efficacy From The European Study Sites Participating In The Phase 2, OPTIC (Phase 3) And OPTIC-X Pivotal Trials
por: Kahaly, George J, et al.
Publicado: (2023)

SAT471 Hearing-Related Adverse Events in Teprotumumab Oncology Clinical Trials
por: Smith, Terry J, et al.
Publicado: (2023)

RF35 | PSAT263 Efficacy of Teprotumumab for Thyroid Eye Disease in Hypothyroid Patients
por: Smith, Terry J, et al.
Publicado: (2022)

Hearing Loss and Teprotumumab
por: Kossler, Andrea, et al.
Publicado: (2021)

SAT-432 Pharmacokinetics (PK) and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor (IGF-1R) Blocking Antibody, in Active Thyroid Eye Disease (TED)
por: Xin, Yan, et al.
Publicado: (2020)

RF35 | PSAT268 Reversal of Graves’ Disease Associated Facial Volume Expansion and Eyelid Changes Following Teprotumumab Therapy
por: Ugradar, Shoaib, et al.
Publicado: (2022)

OR27-04 Efficacy And Safety Results From The Randomized, Placebo-controlled Multicenter Trial With Teprotumumab In Chronic-Low Clinical Activity Score Thyroid Eye Disease Patients
por: Douglas, Raymond S, et al.
Publicado: (2023)

SAT455 A Randomized, Quadruple-masked, Placebo-controlled, Multicenter Trial To Evaluate The Efficacy And Safety Of Teprotumumab In Patients With Chronic (Inactive/Low CAS) Thyroid Eye Disease
por: Douglas, Raymond S, et al.
Publicado: (2023)

FRI572 Teprotumumab In Unexplored Presentation Of Thyroid Eye Disease
por: Torres Torres, Marina T, et al.
Publicado: (2023)

FRI554 Pretibial Myxedema Associated With Hashimoto Thyroiditis Treated With Teprotumumab
por: Marta Niedzialkowska, Ewelina, et al.
Publicado: (2023)

RF35 | PSAT269 Double-Blind, Randomized, Placebo-controlled, Multicenter, Phase 2b Study of Batoclimab in Active and Moderate-to-Severe Thyroid Eye Disease
por: Kahaly, George, et al.
Publicado: (2022)

Improvement of asymmetric thyroid eye disease with teprotumumab
por: Ugradar, Shoaib, et al.
Publicado: (2022)

SAT-424 Assessing Content Validity of the Graves’ Ophthalmopathy Quality of Life Questionnaire (GO-QOL) in the United States
por: Stan, Marius N, et al.
Publicado: (2020)

LBSAT238 Teprotumumab Reduces Orbital Fat And Muscle Volume In Patients With Thyroid Eye Disease
por: Ugradar, Shoaib
Publicado: (2022)

Rapidly Progressive Cognitive Decline and Varicella Zoster Blisters Associated With Teprotumumab in 2 Patients With Graves’ Orbitopathy
por: Hoang, Thanh Duc, et al.
Publicado: (2021)

Teprotumumab for thyroid eye disease: early response is not required for benefit
por: Ugradar, Shoaib, et al.
Publicado: (2021)

PSAT355 A Case Report Identifying Graves’ Ophthalmopathy in a Myasthenia Gravis Crisis and Response to Teprotumumab
por: Zia, Abdul, et al.
Publicado: (2022)

OR26-02 VRDN-001, A Full Antagonist Antibody To IGF-1 Receptor In Development For Thyroid Eye Disease (TED), Binds To A Distinct Epitope From Teprotumumab
por: Bedian, Vahe, et al.
Publicado: (2023)

LBSAT244 Prospective, Blinded, Multicenter Head-to-head Clinical Comparison Of Two "TSI" Assays In Patients With Autoimmune Thyroid Disease
por: Lupo, Mark Armin, et al.
Publicado: (2022)

ODP509 Proof-of-concept, Multicenter, Open-Label Phase 2a Study of Batoclimab in Active and Moderate-to-Severe Thyroid Eye Disease
por: Janes, Jonathan, et al.
Publicado: (2022)

MON-583 Functional Thyrotropin Receptor Antibodies in Pregnant Women with Thyroid Autoimmunity
por: Diana, Tanja, et al.
Publicado: (2019)

OR18-03 Functional TSH Receptor Antibodies Are a Biomarker for Graves’ Disease - a Prospective Trial
por: Kahaly, George Jean, et al.
Publicado: (2020)

SAT-429 Systemic Safety Analysis of Mycophenolate in Graves’ Orbitopathy
por: Lee, Alan C H, et al.
Publicado: (2020)

SAT-557 Functional Thyrotropin Receptor Antibodies Confirm a Novel Graves' Disease Animal Model
por: Diana, Tanja, et al.
Publicado: (2019)

OR26-01 A Novel Small Molecule Thyrotropin Receptor Antagonist
por: Kahaly, George Jean, et al.
Publicado: (2023)

FRI540 A Novel, Rapid, Sensitive Bioassay For Thyrotropin Receptor Stimulatory Antibodies Improves Diagnosis & Management Of Autoimmune Thyroid Disease
por: Jean Kahaly, George, et al.
Publicado: (2023)

FRI537 Thyrotropin Receptor Blocking Antibodies - A Multicenter, 4-Assay Comparison
por: George, Augustine, et al.
Publicado: (2023)

SAT466 Inactive Thyroid Eye Disease Patient Journey
por: Cockerham, Kimberly, et al.
Publicado: (2023)

Pharmacokinetics and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor-Blocking Antibody, in Thyroid Eye Disease
por: Xin, Yan, et al.
Publicado: (2021)

OR19-6 A Novel Anti-CD40 Monoclonal Antibody, Iscalimab, Successfully Treats Graves’ Hyperthyroidism
por: Kahaly, George, et al.
Publicado: (2019)

SUN-621 Lessons from beyond the Graves'
por: Chai, Thora, et al.
Publicado: (2019)

Thyroid dermopathy responds to teprotumumab therapy
por: Crespo-Trevino, Ricaurte, et al.
Publicado: (2022)

Efficacy and Safety of Teprotumumab in Thyroid Eye Disease
por: Teo, Honeylen Maryl, et al.
Publicado: (2021)

Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease
por: Kossler, Andrea Lora, et al.
Publicado: (2022)

SUN-623 Markedly Elevated Thyroglobulin Levels in a Patient with Papillary Thyroid Carcinoma in the Setting of Hashimoto’s Thyroiditis and Negative Imaging: A Case Report
por: Thekkumkattil, Anu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bg9skqg96buajqmug2l1nknq1k